Kirk David Van

US Patent:

6872549, Mar 29, 2005

Filed:

Mar 27, 2003

Appl. No.:

10/400334

Inventors:

Kirk P. Van Ness - Seattle WA, US
Michael T. Trentalange - Seattle WA, US
Bradley D. Dell - Seattle WA, US
Jeffrey T. McGrew - Seattle WA, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

C12P021/02

US Classification:

435 691, 435358, 435377

Abstract:

The invention provides methods of increasing the production of polypeptides, optionally recombinant polypeptides, from mammalian cells using xanthine derivatives or hybrid polar compounds and cultures containing the same. Combinations of inducers including a hybrid polar compound and/or a xanthine derivative and/or an alkanoic acid can also be used, optionally at temperatures less than 37 C.

US Patent:

7288633, Oct 30, 2007

Filed:

Jul 23, 2002

Appl. No.:

10/202699

Inventors:

Stewart D. Lyman - Seattle WA, US
Kirk P. Van Ness - Seattle WA, US
Raymond J. Paxton - Seattle WA, US

Assignee:

Immunex Corporation - Seattle WA

International Classification:

C07K 14/475
C07K 14/52

US Classification:

530351, 530402

Abstract:

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

US Patent:

7452695, Nov 18, 2008

Filed:

Feb 4, 2005

Appl. No.:

11/051149

Inventors:

Kirk P Van Ness - Seattle WA, US
Michael T Trentalange - Seattle WA, US
Bradley D Dell - Seattle WA, US
Jeffrey T McGrew - Madison CT, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

C12P 21/02

US Classification:

435 691, 435375

Abstract:

The invention provides methods of increasing the production of polypeptides, optionally recombinant polypeptides, from mammalian cells using xanthine derivatives or hybrid polar compounds and cultures containing the same. Combinations of inducers including a hybrid polar compound and/or a xanthine derivative and/or an alkanoic acid can also be used, optionally at temperatures less than 37 C.

US Patent:

7709217, May 4, 2010

Filed:

Oct 30, 2007

Appl. No.:

11/981423

Inventors:

Stewart D. Lyman - Seattle WA, US
Kirk P. Van Ness - Bainbridge Island WA, US
Raymond J. Paxton - Bellevue WA, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

G01N 33/53
G01N 33/567

US Classification:

435 71, 435 72

Abstract:

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

US Patent:

7973151, Jul 5, 2011

Filed:

Mar 12, 2010

Appl. No.:

12/723499

Inventors:

Stewart D. Lyman - Seattle WA, US
Kirk P. Van Ness - Bainbridge Island WA, US
Raymond J. Paxton - Bellevue WA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C12N 5/10
C12N 15/19
C12N 15/63
C12N 15/64

US Classification:

536 235, 4352523, 4353201, 435325

Abstract:

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

US Patent:

8598318, Dec 3, 2013

Filed:

Sep 10, 2012

Appl. No.:

13/608808

Inventors:

Stewart D. Lyman - Seattle WA, US
Kirk P. Van Ness - Seattle WA, US
Raymond Paxton - Bellevue WA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 14/475
C07K 14/52
C12N 15/63

US Classification:

530351, 435 695

Abstract:

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

US Patent:

20080260737, Oct 23, 2008

Filed:

Mar 27, 2008

Appl. No.:

12/057133

Inventors:

Rafael A. Ponce - Seattle WA, US
Wayne J. Wallis - Seattle WA, US
Matthew S. Holdren - Seattle WA, US
Linda Zuckerman - Seattle WA, US
Alisa M. Littau - Woodinville WA, US
Kirk P. Van Ness - Bainbridge Island WA, US
Claudia Pena Rossi - Geneva, CH
Hans Otto Lennart Graffner - Helsingborg, SE

International Classification:

A61K 39/395
A61P 37/00

US Classification:

4241341

Abstract:

The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.

US Patent:

20110230637, Sep 22, 2011

Filed:

Jun 1, 2011

Appl. No.:

13/151126

Inventors:

Stewart D. LYMAN - Seattle WA, US
Kirk P. VAN NESS - Bainbridge Island WA, US
Raymond J. PAXTON - Bellevue WA, US

Assignee:

IMMUNEX CORPORATION - Thousand Oaks CA

International Classification:

C07K 14/00
C07K 2/00

US Classification:

530300, 530350

Abstract:

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.